A Pilot Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 07 Jul 2017 Planned End Date changed from 1 Aug 2019 to 1 Jul 2019.
- 07 Jul 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.